全文获取类型
| 收费全文 | 2952篇 |
| 免费 | 128篇 |
| 国内免费 | 31篇 |
专业分类
| 耳鼻咽喉 | 19篇 |
| 儿科学 | 108篇 |
| 妇产科学 | 60篇 |
| 基础医学 | 319篇 |
| 口腔科学 | 31篇 |
| 临床医学 | 329篇 |
| 内科学 | 754篇 |
| 皮肤病学 | 53篇 |
| 神经病学 | 277篇 |
| 特种医学 | 115篇 |
| 外科学 | 406篇 |
| 综合类 | 7篇 |
| 一般理论 | 2篇 |
| 预防医学 | 140篇 |
| 眼科学 | 20篇 |
| 药学 | 248篇 |
| 中国医学 | 3篇 |
| 肿瘤学 | 220篇 |
出版年
| 2023年 | 10篇 |
| 2022年 | 9篇 |
| 2021年 | 53篇 |
| 2020年 | 27篇 |
| 2019年 | 37篇 |
| 2018年 | 60篇 |
| 2017年 | 46篇 |
| 2016年 | 41篇 |
| 2015年 | 57篇 |
| 2014年 | 84篇 |
| 2013年 | 106篇 |
| 2012年 | 227篇 |
| 2011年 | 235篇 |
| 2010年 | 114篇 |
| 2009年 | 112篇 |
| 2008年 | 228篇 |
| 2007年 | 255篇 |
| 2006年 | 197篇 |
| 2005年 | 216篇 |
| 2004年 | 223篇 |
| 2003年 | 201篇 |
| 2002年 | 178篇 |
| 2001年 | 29篇 |
| 2000年 | 27篇 |
| 1999年 | 32篇 |
| 1998年 | 41篇 |
| 1997年 | 32篇 |
| 1996年 | 28篇 |
| 1995年 | 34篇 |
| 1994年 | 19篇 |
| 1993年 | 13篇 |
| 1992年 | 16篇 |
| 1991年 | 17篇 |
| 1990年 | 19篇 |
| 1989年 | 17篇 |
| 1988年 | 7篇 |
| 1987年 | 7篇 |
| 1986年 | 12篇 |
| 1985年 | 8篇 |
| 1984年 | 7篇 |
| 1983年 | 8篇 |
| 1982年 | 5篇 |
| 1981年 | 8篇 |
| 1978年 | 2篇 |
| 1977年 | 1篇 |
| 1976年 | 1篇 |
| 1974年 | 1篇 |
| 1967年 | 1篇 |
| 1966年 | 1篇 |
| 1958年 | 1篇 |
排序方式： 共有3111条查询结果，搜索用时 15 毫秒
1.
2.
J. Gaudelus R. Cohen B. Leboucher J.P. Stahl F. Denis P. Pujol L. Longfier A. Martinot 《Médecine et maladies infectieuses》2019,49(3):180-186
Objectives
Meningococcal C (MenC) vaccination was introduced in the French vaccination calendar in 2010 to reduce the incidence of invasive meningococcal C disease (IMD C), mainly through herd immunity. The Vaccinoscopie survey helps follow vaccination coverage rates (VCRs) of children.Methods
This annual survey is based on a self-administered online questionnaire. In 2017, 4500 mothers of children completed the questionnaire and reported all vaccinations recorded in their child's health record.Results
MenC vaccination was deemed indispensable or useful by 77% to 84% of mothers. The main barrier mentioned by mothers considering the vaccination useless/not very useful, was fear of adverse effects. VCR was estimated at 77% among 24-35-month-old infants, 79% among 6-year-old children, and 50% among 14-15-year-old adolescents. VCR strongly varied depending on the physician's advice for vaccination and on the type of follow-up. Six months after publication of the new French vaccine calendar in April 2017, with a MenC vaccine recommendation for all 5-month-old infants, 43% of infants had received a dose at 6 months of age.Conclusions
VCRs are insufficient to reach herd immunity. Between 2011 and 2017 more than 100 deaths could have been avoided in France if optimal VCRs had been achieved. Faced with this vaccine strategy failure, the new vaccine recommendation at 5 months of age seems well-accepted. This recommendation and the implementation of infant mandatory vaccination in 2018 should have a major impact on IMD C incidence in this age group. 相似文献3.
4.
Renaud Snanoudj Nassim Kamar Elisabeth Cassuto Sophie Caillard Marie Metzger Pierre Merville Antoine Thierry Isabelle Jollet Philippe Grimbert Dany Anglicheau Marc Hazzan Gabriel Choukroun Bruno Hurault De Ligny Bénedicte Janbon Vincent Vuiblet Anne Devys Yann Le Meur Michel Delahousse Jean-Luc Taupin 《Kidney international》2019,95(6):1471-1485
5.
6.
7.
Michael T. Barbe MD Lisa Tonder MS Paul Krack MD PhD Bettina Debû MD Michael Schüpbach MD Steffen Paschen MD Till A. Dembek MD Andrea A. Kühn MD Valerie Fraix MD Christine Brefel-Courbon MD PhD Lars Wojtecki MD PhD David Maltête MD PhD Phillippe Damier MD PhD Friederike Sixel-Döring MD Daniel Weiss MD Marcus Pinsker MD PhD Tatiana Witjas MD PhD Stephane Thobois MD PhD Carmen Schade-Brittinger B.Sc Jörn Rau MSc Jean-Luc Houeto MD PhD Andreas Hartmann MD PhD Lars Timmermann MD PhD Alfons Schnitzler MD PhD Valerie Stoker MPH Marie Vidailhet MD PhD Günther Deuschl MD PhD for the EARLYSTIM study group 《Movement disorders》2020,35(1):82-90
8.
9.
Amélie Huynh Le Maux Bernadette Pignol Delphine Behr-Roussel Jean-Luc Blachon Pierre-Etienne Chabrier Sandrine Compagnie Philippe Picaut Jacques Bernabé Fran?ois Giuliano Pierre Denys 《Toxins》2015,7(12):5462-5471
Intradetrusor injections of Botulinum toxin A—currently onabotulinumtoxinA—is registered as a second-line treatment to treat neurogenic detrusor overactivity (NDO). The common clinical practice is 30 × 1 mL injections in the detrusor; however, protocols remain variable and standardization is warranted. The effect of reducing the number of injection sites of Dysport® abobotulinumtoxinA (aboBoNTA) was assessed in the spinal cord-injured rat (SCI). Nineteen days post-spinalization, female rats received intradetrusor injections of saline or aboBoNTA 22.5 U distributed among four or eight sites. Two days after injection, continuous cystometry was performed in conscious rats. Efficacy of aboBoNTA 22.5 U was assessed versus aggregated saline groups on clinically-relevant parameters: maximal pressure, bladder capacity, compliance, voiding efficiency, as well as amplitude, frequency, and volume threshold for nonvoiding contractions (NVC). AboBoNTA 22.5 U significantly decreased maximal pressure, without affecting voiding efficiency. Injected in four sites, aboBoNTA significantly increased bladder capacity and compliance while only the latter when in eight sites. AboBoNTA significantly reduced NVC frequency and amplitude. This preclinical investigation showed similar inhibiting effects of aboBoNTA despite the number of sites reduction. Further studies are warranted to optimize dosing schemes to improve the risk-benefit ratio of BoNTA-based treatment modalities for NDO and further idiopathic overactive bladder. 相似文献
10.